News & Views | Published:

Gynaecological cancer

Novel molecular subtypes of cervical cancer — potential clinical consequences

Nature Reviews Clinical Oncology volume 14, pages 397398 (2017) | Download Citation

The Cancer Genome Atlas Research Network recently published the most comprehensive, multi-omic molecular characterization of cervical cancers performed to date. The data reveal novel disease subtypes, and provide new insights into the aetiology and pathogenesis of cervical cancer. Importantly, the information obtained has potentially major clinical implications.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370, 734–743 (2014).

  2. 2.

    et al. A phase I trial of paclitaxel, cisplatin and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann. Oncol. 28, 505–511 (2017).

  3. 3.

    Cancer Genome Atlas Research Network. Integrated genomic and molecular characterization of cervical cancer. Nature 543, 378–384 (2017).

  4. 4.

    et al. APOBEC3A functions as a restriction factor of human papillomavirus. J. Virol. 89, 688–702 (2015).

  5. 5.

    Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582 (2015).

  6. 6.

    et al. Somatic mutation in PIK3CA is a late event in cervical carcinogenesis. J. Pathol. Clin. Res. 1, 207–211 (2015).

  7. 7.

    et al. miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am. J. Pathol. 179, 2580–2588 (2011).

  8. 8.

    et al. Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer 52, 56–68 (2013).

  9. 9.

    et al. MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. J. Natl Cancer Inst. 106, dju241 (2014).

  10. 10.

    et al. 5-aza-2′-deoxycytidine (DAC) treatment downregulates the HPV E6 and E7 oncogene expression and blocks neoplastic growth of HPV-associated cancer cells. Oncotarget (2016).

  11. 11.

    et al. Absence of HPV detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am. J. Pathol. 177, 2169–2175 (2010).

  12. 12.

    et al. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG 122, 119–127 (2015).

Download references


C.J.L.M.M. is supported by the European Research Council (ERC advanced programme) via grant ERC-2012-AdG-322986-MASS-CARE.

Author information


  1. Chris J. L. M.Meijer and Renske D. M. Steenbergen are at the Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.

    • Chris J. L. M. Meijer
    •  & Renske D. M. Steenbergen


  1. Search for Chris J. L. M. Meijer in:

  2. Search for Renske D. M. Steenbergen in:

Competing interests

C.J.L.M.M. and R.D.M.S. have minority stakes in Self-Screen, a spin-off company of VU University Medical Center. C.J.L.M.M. has received speakers bureau from GSK, Menarini, Merck, Qiagen, Roche, and Seegene; has occasionally served on the scientific advisory board of GSK, Merck, Qiagen, and Roche; and has occasionally been a consultant for Genticel and Qiagen. Until April 2016, he had shares in Diassay.

Corresponding author

Correspondence to Chris J. L. M. Meijer.

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing